Do Some Inhibitors of COX-2 Increase the Risk of Thromboembolic Events?: Linking Pharmacology with Pharmacoepidemiology

Author： Clark D.W.J.   Layton D.   Shakir S.A.W.  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.27, Iss.7, 2004-01, pp. : 427-456

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

COX-2 inhibitors: increased risk of CV events?

By  

Inpharma, Vol. 1, Iss. 1303, 2001-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Do Inhaled Anticholinergics Increase or Decrease the Risk of Major Cardiovascular Events?: A Synthesis of the Available Evidence

By Salpeter Shelley R.  

Drugs, Vol. 69, Iss. 15, 2009-10 ,pp. : 2025-2033

Adis International

Access to resources Recommend Favorite

The Second Generation of COX-2 Inhibitors: What Advantages Do the Newest Offer?

By Stichtenoth D.O.   Frölich J.C.  

Drugs, Vol. 63, Iss. 1, 2003-01 ,pp. : 33-45

Adis International

Access to resources Recommend Favorite

Inhaled anticholinergics: increased risk of major adverse CV events?

By  

Inpharma, Vol. 1, Iss. 1658, 2008-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Selective COX-2 inhibitors for acute gout?

By  

Inpharma, Vol. 1, Iss. 1363, 2002-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite